Published in J Clin Invest on April 01, 2002
MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem (2009) 2.24
Divergent functions of murine Pax3 and Pax7 in limb muscle development. Genes Dev (2004) 2.12
Integrins in invasive growth. J Clin Invest (2002) 1.96
An overview of the c-MET signaling pathway. Ther Adv Med Oncol (2011) 1.95
Invasive growth: from development to metastasis. J Clin Invest (2002) 1.91
Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J (2005) 1.89
c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol (2011) 1.81
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol (2012) 1.77
Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol (2009) 1.76
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog (2008) 1.68
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res (2013) 1.52
Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem (2011) 1.45
Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget (2015) 1.16
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci U S A (2003) 1.15
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol (2009) 1.14
Targeting MET Amplification as a New Oncogenic Driver. Cancers (Basel) (2014) 1.11
Negative feedback regulation of Met-dependent invasive growth by Notch. Mol Cell Biol (2005) 1.10
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther (2010) 1.07
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer (2011) 1.06
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg (2005) 1.06
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer (2009) 1.03
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther (2014) 1.01
STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem (2009) 0.95
Diacylglycerol kinase-alpha mediates hepatocyte growth factor-induced epithelial cell scatter by regulating Rac activation and membrane ruffling. Mol Biol Cell (2007) 0.95
A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem (2010) 0.95
Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy. Oncoscience (2013) 0.92
Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling. Oncogene (2007) 0.92
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer (2014) 0.92
Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity. J Biol Chem (2012) 0.91
Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget (2016) 0.89
Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget (2015) 0.88
Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. Oncotarget (2015) 0.86
Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer (2012) 0.86
Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation. Biochemistry (2008) 0.86
FOXC2 promotes colorectal cancer metastasis by directly targeting MET. Oncogene (2014) 0.85
Rhabdomyosarcomas: an overview on the experimental animal models. J Cell Mol Med (2012) 0.84
MET and Small-Cell Lung Cancer. Cancers (Basel) (2014) 0.83
P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin. Exp Cell Res (2006) 0.83
C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol (2012) 0.83
Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch (2012) 0.82
Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. Cancer Res Treat (2005) 0.82
Molecular imaging for guiding oncologic prognosis and therapy in esophageal adenocarcinoma. Hosp Pract (1995) (2011) 0.82
MicroRNA-1 in Cardiac Diseases and Cancers. Korean J Physiol Pharmacol (2014) 0.82
The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice. J Biol Chem (2009) 0.81
Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res (2013) 0.80
Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met. Phytother Res (2016) 0.79
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis (2012) 0.79
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer (2014) 0.79
Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacol Sin (2013) 0.78
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer (2015) 0.78
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol (2006) 0.77
MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clin Exp Metastasis (2009) 0.77
Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. Oncotarget (2016) 0.77
Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. J Cancer Res Clin Oncol (2016) 0.76
Differential expression of genes encoding proteins of the HGF/MET system in insulinomas. Diabetol Metab Syndr (2015) 0.76
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
Development of antibody-based c-Met inhibitors for targeted cancer therapy. Immunotargets Ther (2015) 0.75
MET overexpression and gene amplification in NSCLC: a clinical perspective. Lung Cancer (Auckl) (2013) 0.75
Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review. EJNMMI Res (2017) 0.75
PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget (2017) 0.75
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest (2002) 3.23
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A (1997) 2.92
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol (2001) 2.72
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem (2000) 2.46
A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene (2000) 2.27
Invasive growth: from development to metastasis. J Clin Invest (2002) 1.91
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res (1999) 1.74
Cross-talk between the proto-oncogenes Met and Ron. Oncogene (2000) 1.71
The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene (1995) 1.66
Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol (1993) 1.64
Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J (1997) 1.60
Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc Natl Acad Sci U S A (1996) 1.58
Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem (1999) 1.58
Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol (2001) 1.58
Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst (1999) 1.44
Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest (1996) 1.27
Evidence for non-covalent clusters of the c-met proto-oncogene product. Oncogene (1992) 1.16
Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44. Mol Cell Biol (2000) 1.10
Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). Oncogene (1994) 1.09
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci U S A (1998) 1.07
Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor). Mol Cell Biol (1991) 1.06
Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am J Pathol (2000) 1.04
Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins (2001) 1.02
Different point mutations in the met oncogene elicit distinct biological properties. FASEB J (2000) 1.01
Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer (1999) 0.99
Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity. J Biol Chem (1996) 0.97
Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor. Oncogene (1998) 0.95
Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src. Oncogene (2000) 0.90
Cross-talk between CD44 and c-Met in B cells. Curr Top Microbiol Immunol (1999) 0.84
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
The genetic basis of cancer of the kidney. J Urol (2003) 3.45
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med (2007) 2.19
Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol (2007) 1.86
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat (2004) 1.78
Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. Mod Pathol (2004) 1.67
A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum Mol Genet (2003) 1.66
Effects of different fixatives on beta-galactosidase activity. J Histochem Cytochem (2002) 1.63
Focus on kidney cancer. Cancer Cell (2004) 1.53
Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res (2003) 1.46
Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res (2004) 1.45
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol (2012) 1.45
A germ-line insertion in the Birt-Hogg-Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer. Proc Natl Acad Sci U S A (2004) 1.40
Hereditary renal cancers. Radiology (2003) 1.31
Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol (2004) 1.20
Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. Lab Invest (2006) 1.00
The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU Int (2005) 0.98
Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum Mutat (2013) 0.92
Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21). Hum Mol Genet (2002) 0.84
Facial papules, spontaneous pneumothorax, and renal tumors. J Am Acad Dermatol (2003) 0.76